HUP0203057A2 - Módosított ciliáris nerotróf faktor, ennek előállítási és használati módszere - Google Patents

Módosított ciliáris nerotróf faktor, ennek előállítási és használati módszere

Info

Publication number
HUP0203057A2
HUP0203057A2 HU0203057A HUP0203057A HUP0203057A2 HU P0203057 A2 HUP0203057 A2 HU P0203057A2 HU 0203057 A HU0203057 A HU 0203057A HU P0203057 A HUP0203057 A HU P0203057A HU P0203057 A2 HUP0203057 A2 HU P0203057A2
Authority
HU
Hungary
Prior art keywords
neurotrophic factor
making
ciliary neurotrophic
methods
modified ciliary
Prior art date
Application number
HU0203057A
Other languages
English (en)
Inventor
Philip D. Lambert
Mark W. Sleeman
Stanley J. Wiegand
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/454,380 external-priority patent/US6680291B1/en
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HUP0203057A2 publication Critical patent/HUP0203057A2/hu
Publication of HUP0203057A3 publication Critical patent/HUP0203057A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya az Ax-15 módosított ciliáris neurotróf faktorhasználata olyan gyógyszer előállításában, amit diabetesz, főleg neminzulin dependens diabetesz mellitusz vagy terhességi diabeteszkezelési eljárásában használnak. Ó
HU0203057A 1999-08-13 2000-07-27 Modified ciliary neurotrophic factor, method of making and methods of use thereof HUP0203057A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37383499A 1999-08-13 1999-08-13
US09/454,380 US6680291B1 (en) 1998-02-27 1999-12-03 Modified ciliary neurotrophic factor, method of making and methods of use thereof
PCT/US2000/020432 WO2001012810A1 (en) 1999-08-13 2000-07-27 Modified ciliary neurotrophic factor, method of making and methods of use thereof

Publications (2)

Publication Number Publication Date
HUP0203057A2 true HUP0203057A2 (hu) 2002-12-28
HUP0203057A3 HUP0203057A3 (en) 2005-07-28

Family

ID=27006327

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203057A HUP0203057A3 (en) 1999-08-13 2000-07-27 Modified ciliary neurotrophic factor, method of making and methods of use thereof

Country Status (10)

Country Link
EP (1) EP1200589A1 (hu)
JP (1) JP2003507393A (hu)
CN (1) CN1387568A (hu)
AU (1) AU6382200A (hu)
BR (1) BR0013204A (hu)
CA (1) CA2379940A1 (hu)
HU (1) HUP0203057A3 (hu)
IL (1) IL148033A0 (hu)
PL (1) PL364931A1 (hu)
WO (1) WO2001012810A1 (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379655A2 (en) * 2001-03-02 2004-01-14 MERCK PATENT GmbH Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity
CN100439396C (zh) * 2004-04-02 2008-12-03 西南生物工程产业化中试基地有限公司 人睫状神经营养因子的衍生物多肽及其制备方法和应用
CN100457778C (zh) * 2005-09-02 2009-02-04 中国药品生物制品检定所 睫状神经营养因子(cntf)突变体及其生产方法和其用途
CN101144082B (zh) * 2007-06-12 2012-09-05 兰州生物制品研究所有限责任公司 重组人睫状神经营养因子、突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
CN1250379A (zh) * 1997-01-23 2000-04-12 住友制药株式会社 糖尿病治疗剂

Also Published As

Publication number Publication date
BR0013204A (pt) 2004-02-17
CN1387568A (zh) 2002-12-25
WO2001012810A1 (en) 2001-02-22
CA2379940A1 (en) 2001-02-22
IL148033A0 (en) 2002-09-12
PL364931A1 (en) 2004-12-27
JP2003507393A (ja) 2003-02-25
HUP0203057A3 (en) 2005-07-28
AU6382200A (en) 2001-03-13
EP1200589A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
DK1056856T3 (da) Modificeret ciliarneurotrofisk faktor samt fremgangsmåder til dannelse og anvendelse deraf
HUP0400689A2 (hu) ABCA-1 szint-emelő vegyületek
HUP0203601A2 (hu) Mono-amino-oxidáz inhibitorok alkalmazása elhízás kezelésére szolgáló gyógyszerek előállítására
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
ATE253912T1 (de) Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca
AU5976500A (en) Use of photocatalytic preparations of colloidal titanium dioxide for preserving the original appearance of cementitious, stone, or marble products
DE60116066D1 (de) Titanium mit verminderter anfälligkeit für verfärbung in der atmosphäre und herstellungsverfahren dafür
DE60230869D1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
HUP0400648A2 (hu) Ecteinascidin-743-t tartalmazó tumorellenes kezeléseknél alkalmazható készítmények
IT1305313B1 (it) 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
ATE265454T1 (de) Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
DE50305587D1 (en) 2-heteroarylcarbonsäureamide
IT1307724B1 (it) Fibra di ceramica, metallo o carbonio rivestita e procedimento diproduzione
BR0209541A (pt) Uso das imidazotriazinonas 2-fenil-substituìdas
HUP9700806A2 (hu) Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására
PT1360187E (pt) 3,7-diazabiciclo(3.3.0)octanos e a sua utilizacao no tratamento de arritmias cardiacas
HUP0203057A2 (hu) Módosított ciliáris nerotróf faktor, ennek előállítási és használati módszere
HUP0200475A2 (hu) Perfluor-alkil-amidok, azok előállítása, és diagnosztikai alkalmazása
NO894532L (no) Titandioksyd, fremgangsmaate for dets fremstilling og anvendelse derav.
HUP0402298A2 (hu) Dezoxipeganin alkalmazása klinikai depresszió kezelésére
HUP0102116A2 (hu) Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása
WO2002080962A8 (en) Papaine containing pharmaceutical formulation resp. its use
CA2304899A1 (en) New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of non-cardiac origin or with gastro-esophageal reflux disease

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished